Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Report 2026

The cell and gene therapy contract development and manufacturing organization (cdmo) market size has grown exponentially in recent years. It will grow from $6.92 billion in 2025 to $8.85 billion in 2026 at a compound annual growth rate (CAGR) of 27.8%. The growth in the historic period can be attributed to increasing outsourcing of advanced therapy manufacturing, limited in-house development capabilities, growth of early-stage biotech companies, expansion of orphan drug development, increasing need for specialized expertise.

The cell and gene therapy contract development and manufacturing organization (cdmo) market size is expected to see exponential growth in the next few years. It will grow to $21.35 billion in 2030 at a compound annual growth rate (CAGR) of 24.6%. The growth in the forecast period can be attributed to increasing commercialization of gene-modified therapies, rising demand for flexible manufacturing capacity, expansion of global cdmo partnerships, growing investment in cell therapy pipelines, increasing regulatory approvals for advanced therapies. Major trends in the forecast period include expansion of end-to-end cdmo service offerings, growing demand for commercial-scale manufacturing support, rising adoption of advanced gene editing platforms, increasing focus on accelerated development timelines, enhanced integration of regulatory support services.

The rising incidence of cancer is expected to drive the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market in the coming years. Cancer encompasses a group of diseases marked by the uncontrolled growth and spread of abnormal cells in the body. The increasing number of cancer cases is attributed to aging populations, lifestyle changes, environmental factors, and advancements in detection methods. Cell and gene therapy CDMOs contribute to reducing cancer burden by developing and manufacturing innovative, targeted therapies that improve treatment effectiveness and patient outcomes. For example, in July 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that in 2023, approximately 165,000 Australians were newly diagnosed with cancer, which corresponds to more than 450 cases per day, with males accounting for about 55% of these cases. Thus, the rising incidence of cancer fuels the growth of the cell and gene therapy CDMO market.

Major companies in the cell and gene therapy contract development and manufacturing organization (CDMO) market are focusing on expanding their offerings with advanced solutions such as PluriMatrix technology to improve the scalability, efficiency, and quality of cell-based product manufacturing. PluriMatrix technology is a proprietary platform designed for the large-scale production of cell-based products. This technology enables the 3D expansion of cells on an industrial scale, ensuring high yield and consistent quality through an automated, fully controlled, and validated process. For example, in January 2024, Pluri, an Israel-based biotech company, launched PluriCDMO, a new business unit providing cell therapy manufacturing services as a contract development and manufacturing organization (CDMO). The division includes a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri's newly formed division delivers end-to-end services from early preclinical stages to late-stage clinical trials and commercialization, including process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as noted in a company announcement. It leverages the company's advanced PluriMatrix technology to provide sophisticated cell therapy manufacturing services.

In November 2023, Ajinomoto Co. Inc., a Japan-based food and biotechnology corporation, acquired Forge Biologics for $620 million. Through this acquisition, Ajinomoto strengthens its global capabilities in adeno-associated virus (AAV) and plasmid gene therapy manufacturing, enhancing and reinforcing its existing contract development and manufacturing services. Forge Biologics is a US-based gene therapy contract development and manufacturing organization (CDMO) and clinical-stage therapeutics company.

Major companies operating in the cell and gene therapy contract development and manufacturing organization (cdmo) market are Lonza Group, Catalent Inc, Thermo Fisher Scientific Inc, Samsung Biologics Co Ltd, WuXi Biologics, AGC Biologics, FUJIFILM Diosynth Biotechnologies, Oxford BioMedica Plc, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Avid Bioservices Inc, Charles River Laboratories International Inc, VGXI Inc, Genezen Laboratories Inc, OmniaBio Inc, Pluri Inc, Cell and Gene Therapy Catapult, BioVectra Inc, Porton Advanced Solutions Ltd.

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell and gene therapy contract development and manufacturing organization (cdmo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the cell and gene therapy CDMO market by increasing costs of imported manufacturing equipment, viral vector components, analytical tools, and single-use systems required for development and production. CDMOs in North America and Europe are most affected due to reliance on specialized imported inputs, while Asia-Pacific faces pricing pressure on exported CDMO services. These tariffs are raising project costs and affecting client pricing structures. However, they are also driving regional capacity expansion, domestic equipment sourcing, and long-term investments in localized CDMO infrastructure.

The cell and gene therapy contract development and manufacturing organization (cdmo) market research report is one of a series of new reports that provides cell and gene therapy contract development and manufacturing organization (cdmo) market statistics, including cell and gene therapy contract development and manufacturing organization (cdmo) industry global market size, regional shares, competitors with a cell and gene therapy contract development and manufacturing organization (cdmo) market share, detailed cell and gene therapy contract development and manufacturing organization (cdmo) market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy contract development and manufacturing organization (cdmo) industry. This cell and gene therapy contract development and manufacturing organization (cdmo) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A cell and gene therapy contract development and manufacturing organization (CDMO) is a specialized company that provides services to support the development, production, and commercialization of cell-based and gene therapy products. These organizations deliver services designed to meet the specific needs of companies developing advanced therapies, including biopharmaceutical firms, academic institutions, and government agencies. Cell and gene therapy CDMOs play a vital role in accelerating the development and commercialization of advanced therapy products by providing specialized expertise, infrastructure, and services to support their clients’ requirements from early-stage development through commercialization.

The primary product types of cell and gene therapy contract development and manufacturing organizations (CDMOs) include gene therapy, gene-modified cell therapy, and cell therapy. Gene therapy involves altering or manipulating the genes within a person’s cells to treat or prevent disease. The development process encompasses various phases, including phase 1, phase 2, phase 3, and phase 4, for multiple indications such as oncology, infectious diseases, neurological disorders, rare diseases, and others.

The cell and gene therapy contract development and manufacturing organization (CDMO) market includes revenues earned by contract development and manufacturing organizations providing services for the development, manufacturing, and testing of cell and gene therapy products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.